Compare
Rallybio Corp vs Rafael Holdings, Inc. vs Shattuck Labs, Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | Rallybio Corp RLYB | Rafael Holdings, Inc. RFL | Shattuck Labs, Inc. STTK | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-07-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $858.0K | $917.0K | $1.00M | $1.01M |
| Revenue growth (YoY) | +34.9% | +44.0% | -82.5% | +65.5% |
| Gross margin | n/a | n/a | n/a | 22.3% |
| Operating margin | n/m | n/m | n/m | -771.6% |
| Net margin | n/m | n/m | n/m | -732.5% |
| Net income | -$8.98M | -$30.52M | -$48.81M | -$7.37M |
| EPS (Diluted) | -$1.59 | -$1.04 | -$0.70 | -$11.73 |
| Operating cash flow | -$29.81M | -$18.92M | -$39.88M | -$6.85M |
| Free cash flow | n/a | -$18.93M | -$39.95M | -$6.99M |
| Cash & equivalents | $31.37M | $52.77M | $54.19M | $1.51M |
| Total assets | $62.26M | $114.11M | $91.03M | $5.37M |
| Total liabilities | $4.30M | $15.74M | $8.64M | $1.99M |
| Shareholders' equity | $57.96M | $98.37M | $82.39M | $3.46M |
| Return on year-end equity | -15.5% | -31.0% | -59.2% | -212.7% |
| Shares outstanding | 5.28M | n/a | 63.28M | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | Rallybio Corp | Rafael Holdings, Inc. | Shattuck Labs, Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $858.0K Ended 2025-12-31 | $917.0K Ended 2025-07-31 | $1.00M Ended 2025-12-31 | $1.01M Ended 2025-12-31 |
| 1 year earlier | $636.0K Ended 2024-12-31 | $637.0K Ended 2024-07-31 | $5.72M Ended 2024-12-31 | $607.6K Ended 2024-12-31 |
| 2 years earlier | n/a | $279.0K Ended 2023-07-31 | $1.66M Ended 2023-12-31 | $253.6K Ended 2023-12-31 |
| 3 years earlier | n/a | $410.0K Ended 2022-07-31 | $652.0K Ended 2022-12-31 | $223.2K Ended 2022-12-31 |
| 4 years earlier | n/a | $802.0K Ended 2021-07-31 | $30.02M Ended 2021-12-31 | n/a |